Cancer Therapy-Induced Cardiovascular Toxicity Treatment with apolipoprotein A1 protects mice against doxorubicin-induced cardiotoxicity in a scavenger receptor class B, type I-dependent manner
Cancer Therapy-Induced Cardiovascular Toxicity Treatment with apolipoprotein A1 protects mice against doxorubicin-induced cardiotoxicity in a scavenger receptor class B, type I-dependent manner
复制标题
DOI:
--
复制
发表时间:
--
期刊:
影响因子:
--
通讯作者:
中科院分区:
文献类型:
--
作者:
a scavenger receptor type an agent used to treat a variety of cancers, is cardiotoxic by triggering cardiomyocyte apoptosis. We previously showed that treating cultured cardiomyocytes with human high-density lipoprotein in vitro or transgenic overexpression of human apolipoprotein A1, its main structural protein, protects against doxo-rubicin-induced cardiomyocyte apoptosis in a manner dependent on the scavenger receptor class B type I [Durham KK, Chathely KM, Mak KC, Momen A, Thomas CT, Zhao YY, MacDonald ME, Curtis JM, Husain M, Trigatti BL. HDL protects against doxorubicin-induced cardiotoxicity in a scavenger receptor class B type 1-, phosphatidylinositol 3-kinase-, and Akt-dependent manner. Am J Physiol Heart Software, La Jolla, CA). For pairwise comparisons, normality was assessed using the Shapiro-Wilk or D’Agostino-Pearson omnibus test and equal variance by F -test. Data that passed were analyzed by Student’s t -test (2-tailed, unpaired), while data that did not pass the normality test were analyzed by the Mann-Whitney rank-sum test. One-way ANOVA was used for data comprising multiple groups, and two-way ANOVA was used for data with two or more independent variables. Post hoc analysis was performed using the Tukey test for groups of equal sample size or the Tukey-Kramer test for groups with unequal sample size. Differences are considered statistically significant at P (cid:6) 0.05.